Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term ...

Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared, and it initiated a Phase 1/2a clinical trial (NCT07020221), VS-7375-101, in May 2025.

Verastem’s approval of Avmapki Fakzynja Co-Pack positions the company as a key player in the LGSOC treatment landscape. This milestone has contributed to the stock’s impressive 53% return over ...

Verastem (VSTM) announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel ...

Verastem’s approval of Avmapki Fakzynja Co-Pack positions the company as a key player in the LGSOC treatment landscape. This milestone has contributed to the stock’s impressive 53% return over the ...

Verastem continues to focus on innovative therapies, with its pipeline aimed at addressing unmet needs in oncology. The company’s recent presentations at ASCO and subsequent discussions provide a ...

TEM's Genomics revenues soar 89% on oncology test gains and Ambry Genetics' boost. New assays could fuel more growth.